Phase I/II clinical trial of WT1 peptide vaccine for the children with malignancies

Phase I/II clinical trial of WT1 peptide vaccine for the children with malignancies - WT1 peptide vaccination to the children with malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002990

Enrollment

Registered

2010-01-12

Start date

2004-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric acute leukemia or pediatric malignant solid tumors

Interventions

WT1 peptide + montanide adjuvant. every week x 12 times (= 3 months).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: <main inclusion criteria> Tumor cells: WT1 expression (+). HLA: A2402(+). Residual tumor or tumor marker (+), or high risk of relapse. Others.

Exclusion criteria

Exclusion criteria: <main exclusion criteria> MDS and/or MPN before allogeneic HSCT. Inappropriate condition. Others.

Design outcomes

Primary

Measure	Time frame
Adverse event rate (phase I) and anti-tumor effect (phase II)	—

Countries

Japan

Contacts

Public ContactAkihisa Sawada

Osaka Medical Center and Research Institute for Hematology/Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026